Flow Pharma is structured around development of therapeutic vaccines for breast cancer and cervical cancer caused by the HPV virus. The firm's pipeline includes FlowVax triple negative Breast Cancer vaccine, and Ebola / Marburg vaccines for the DoD US Army - the latter using a powerful AI computational model and a dry powder vaccine/ patented manufacturing process, which requires no refrigeration. Unlike CAR-T, the firm's low cost, peptide formulations are non-toxic and utilize highly specific Class 1 and Class 2 epitopes to attack killer T-cells which produce an immediate positive immune response. The firm was early designed around the vaccine development platform intended to design synthetic, neoantigen based, Immuno-Oncology therapeutics. The company's platform uses artificial intelligence and deep learning to select small peptides called neoantigens on the surface of cancer cells optimal for killer T-cell attack identified by gene sequencing a patient's cancer cells, enabling patients with vaccines to treat their cancer disease.
